Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
No results matched your search
Switzerland Stocks
Switzerland
- Austria
- Belgium
- Bosnia-Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Montenegro
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Russia
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
| Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| Credit Suisse | 11.10 | 11.31 | 11.10 | +0.10 | +0.86% | 11.12M | 07/12 | ||
| Adecco | 46.57 | 47.35 | 46.45 | +0.41 | +0.89% | 1.15M | 07/12 | ||
| Richemont | 64.02 | 64.80 | 63.98 | +0.66 | +1.04% | 1.66M | 07/12 | ||
| Julius Baer | 37.10 | 38.29 | 37.04 | -0.45 | -1.20% | 2.08M | 07/12 | ||
| ABB | 18.95 | 19.17 | 18.92 | +0.07 | +0.37% | 5.40M | 07/12 | ||
| LafargeHolcim | 42.16 | 42.83 | 41.88 | +0.52 | +1.25% | 2.36M | 07/12 | ||
| Zurich Insurance Group | 300.10 | 303.10 | 299.70 | +2.90 | +0.98% | 600.44K | 07/12 | ||
| Swatch I | 291.10 | 297.40 | 291.10 | -0.10 | -0.03% | 311.77K | 07/12 | ||
| Swiss Life Holding | 382.20 | 386.00 | 380.30 | +5.70 | +1.51% | 247.03K | 07/12 | ||
| Novartis | 87.00 | 88.86 | 86.00 | -0.36 | -0.41% | 8.28M | 07/12 | ||
| Nestle | 84.80 | 85.38 | 83.56 | +1.66 | +2.00% | 6.65M | 07/12 | ||
| Swiss Re | 89.28 | 89.68 | 88.50 | +1.78 | +2.03% | 1.40M | 07/12 | ||
| Roche Holding Participation | 250.70 | 253.25 | 247.05 | +3.40 | +1.37% | 1.68M | 07/12 | ||
| Lonza Group | 307.60 | 311.80 | 306.90 | -0.50 | -0.16% | 276.40K | 07/12 | ||
| Swisscom | 476.40 | 480.10 | 472.20 | +6.60 | +1.40% | 159.42K | 07/12 | ||
| SGS | 2,332.00 | 2,366.00 | 2,319.00 | +18.00 | +0.78% | 22.14K | 07/12 | ||
| Geberit | 377.90 | 384.10 | 377.90 | +1.90 | +0.51% | 149.09K | 07/12 | ||
| Sika | 123.50 | 125.40 | 123.00 | +1.60 | +1.31% | 575.74K | 07/12 | ||
| UBS Group | 12.56 | 12.80 | 12.56 | +0.06 | +0.48% | 14.90M | 07/12 | ||
| Givaudan | 2,426.00 | 2,437.00 | 2,387.00 | +54.00 | +2.28% | 32.44K | 07/12 |
Stock Market News
Gilead Sciences snares Roche executive O'Day as CEO
By Reuters - Dec 10, 2018
(Reuters) - Drugmaker Gilead Sciences Inc (NASDAQ:GILD) on Monday named Roche Holding (SIX:ROG) AG executive Daniel O'Day as its new chief executive, tapping an industry...
Julius Baer in talks with Santander over Venezuela business: sources
By Reuters - Dec 08, 2018
ZURICH (Reuters) - Swiss private bank Julius Baer (S:BAER) is in talks about transferring its Venezuelan book of business to Spain's Banco Santander (MC:SAN) as Baer...
Exclusive: Activist investor Elliott has stake in Germany's Bayer - sources
By Reuters - Dec 07, 2018
By Arno Schuetze and Greg Roumeliotis FRANKFURT/NEW YORK (Reuters) - Activist investor Elliott has taken a position in Germany's Bayer (DE:BAYGn), adding to the slew of...
Stock Markets Analysis & Opinion
Roche's Kadcyla Halves Death Risk In Breast Cancer Study
By Zacks Investment Research - Dec 06, 2018
Roche (OTC:RHHBY) announced that its breast cancer drug, Kadcyla significantly reduced the risk of disease recurrence by 50% as adjuvant (after surgery) therapy in phase III KATHERINE study compared...
AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study
By Zacks Investment Research - Dec 05, 2018
AbbVie, Inc. (NYSE:ABBV) announced that it has stopped enrollments in a pivotal phase III study —TAHOE — evaluating its cancer candidate rovalpituzumab tesirine or Rova-T in second-line...
J&J's Blood Cancer Drugs Succeed In Label Expansion Studies
By Zacks Investment Research - Dec 04, 2018
Johnson & Johnson (NYSE:JNJ) presented positive data from late-stage label expansion studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in previously untreated patients at the...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
